On Sept. 1, 2026, Vertex Pharmaceuticals announced the successful completion of the acquisition of Crinetics Pharmaceuticals, a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases. Vertex also announced the expansion of its executive leadership team, in support of the Company’s continued growth and diversification.

As announced on July 6, 2026, Vertex entered into a definitive agreement with Crinetics Pharmaceuticals, whereby Vertex would acquire Crinetics for a total equity value of approximately $10.0 billion, or approximately $8.8 billion net of estimated cash acquired, subject to certain closing conditions. Following the receipt of necessary regulatory clearances and the approval by Crinetics’ shareholders, Vertex completed its acquisition of Crinetics on September 1, 2026.

The Crinetics acquisition adds to Vertex’s innovation pipeline, accelerates revenue growth, and enhances the long-term earnings profile of the Company. The acquisition brings PALSONIFY^® (paltusotine) and atumelnant, in addition to several other pipeline programs. PALSONIFY is the first and only once-daily oral therapy for acromegaly; it has been launched in the U.S., approved in the EU and is under review by other global regulatory bodies. Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist, is in Phase 3 development for congenital adrenal hyperplasia (CAH) and in Phase 2 development for Cushing’s syndrome. At peak, PALSONIFY and atumelnant have the potential to deliver more than $5 billion in combined annual revenue. The transaction is expected to become accretive to non-GAAP operating income in 2029.